Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

References

• Chiaravalli M, Reni M, O’Reilly EM. Pancreatic ductal adenocarcinoma: state-of-the-art 2017 and new therapeutic strategies. Cancer Treat Rev. 2017;60:32–43. doi:10.1016/j.ctrv.2017.08.007.
   PubMed Web of Science ®Google Scholar
• Wang LM, Silva MA, D’Costa Z, Bockelmann R, Soonawalla Z, Liu S, O’Neill E, Mukherjee S, McKenna WG, Muschel R, et al. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7:4183–94. doi:10.18632/oncotarget.6770.
   PubMedGoogle Scholar
• Martinez-Bosch N, Vinaixa J, Navarro P. Immune evasion in pancreatic cancer: from mechanisms to therapy. Cancers (Basel). 2018; 10(1). pii: E6. doi: 10.3390/cancers10010006.
   Web of Science ®Google Scholar
• Tocheva AS, Mor A. Checkpoint inhibitors: applications for autoimmunity. Curr Allergy Asthma Rep. 2017;17:72. doi:10.1007/s11882-017-0740-z.
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al. Comprehensive analyses of tumor immunity: implications for Cancer immunotherapy. Genome Biol. 2016;17(1):174. doi: 10.1186/s13059-016-1028-7.
   Google Scholar
• Pardoll DM. The blockade of immune Slide checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Benyamine A, Le Roy A, Mamessier E, Gertner-Dardenne J, Castanier C, Orlanducci F, Pouyet L, Goubard A, Collette Y, Vey N, et al. BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia. OncoImmunology. 2016;5:e1146843–e. doi:10.1080/2162402X.2016.1146843.
   PubMed Web of Science ®Google Scholar
• Benyamine A, Loncle C, Foucher E, Blazquez JL, Castanier C, Chrétien AS, Modesti M, Secq V, Chouaib S, Gironella M, et al. BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). OncoImmunology. 2017;7:e1372080–e. doi:10.1080/2162402X.2017.1372080.
   PubMed Web of Science ®Google Scholar
• Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest. 2010;120:157–67. doi:10.1172/JCI40070.
   PubMed Web of Science ®Google Scholar
• Lan X, Li S, Gao H, Nanding A, Quan L, Yang C, Ding S, Xue Y. Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis. OncoTargets Ther. 2017;10:919–26. doi:10.2147/OTT.S128825.
   PubMed Web of Science ®Google Scholar
• Tsai KK, Daud AI. The role of anti-PD-1/PD-L1 agents in melanoma: progress to date. Drugs. 2015;75:563–75. doi:10.1007/s40265-015-0376-z.
   PubMed Web of Science ®Google Scholar
• Meng X, Liu Y, Zhang J, Teng F, Xing L, Yu J. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: new development and challenges. Cancer Lett. 2017;405:29–37. doi:10.1016/j.canlet.2017.06.033.
   PubMed Web of Science ®Google Scholar
• Feng M, Xiong G, Cao Z, Yang G, Zheng S, Song X, You L, Zheng L, Zhang T, Zhao Y. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Lett. 2017;407:57–65. doi:10.1016/j.canlet.2017.08.006.
   PubMed Web of Science ®Google Scholar
• Huang S-Y, Lin -H-H, Lin C-W, Li -C-C, Yao M, Tang J-L, Hou H-A, Tsay W, Chou S-J, Cheng C-L, et al. Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma. Oncotarget. 2016;7:62490–502. doi:10.18632/oncotarget.11519.
   PubMedGoogle Scholar
• Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev. 2012;38:843–53. doi:10.1016/j.ctrv.2011.12.004.
   PubMed Web of Science ®Google Scholar
• Kruger S, Legenstein M-L, Rösgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, et al. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. OncoImmunology. 2017;6:e1310358–e. doi:10.1080/2162402X.2017.1310358.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine (United States). 2017;96:e6369–e.
   Google Scholar
• Guo X, Wang J, Jin J, Chen H, Zhen Z, Jiang W, Lin T, Huang H, Xia Z, Sun X. High serum level of soluble programmed death ligand 1 is associated with a poor prognosis in hodgkin lymphoma. Translational Oncology. 2018;11:779–85. doi:10.1016/j.tranon.2018.03.012.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Doi T, Obayashi K, Hirai A, Yoneda K, Tanaka F, Iwai Y. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. Immunology Letters. 2018;196:155–60. doi:10.1016/j.imlet.2018.01.007.
   PubMed Web of Science ®Google Scholar
• Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Int Med. 2013;4:627–35.
   PubMedGoogle Scholar
• Gong J, Chehrazi-Raffle A, Reddi S, Salgia R, Feng M, Xiong G, Cao Z, Yang G, Zheng S, Song X, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations. J Immun Ther Cancer. 2018;6:8. doi:10.1186/s40425-018-0316-z.
   PubMed Web of Science ®Google Scholar
• Wang J, Reiss KA, Khatri R, Jaffee E, Laheru D. Immune therapy in GI malignancies: A review. J Clin Oncol. 2015;33:1745–53. doi:10.1200/JCO.2015.60.7879.
   PubMed Web of Science ®Google Scholar
• Kunk PR, Bauer TW, Slingluff CL, Rahma OE. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immun Ther Cancer. 2016;4:14. doi:10.1186/s40425-016-0119-z.
   PubMed Web of Science ®Google Scholar
• Zheng L. PD-L1 expression in pancreatic cancer. J Natl Cancer Inst. 2017;109(6). doi: 10.1093/jnci/djw304. Print 2017 Jan.
   Google Scholar
• Alsaif M, Guest PC, Schwarz E, Reif A, Kittel-Schneider S, Spain M, Rahmoune H, Bahn S. Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selection. Proteomics Clin Appl. 2012;6:297–303. doi:10.1002/prca.201100061.
   PubMed Web of Science ®Google Scholar
• O’Neal WK, Anderson W, Basta PV, Carretta EE, Doerschuk CM, Barr RG, Bleecker ER, Christenson SA, Curtis JL, Han MK, et al. Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. J Transl Med. 2014;12:9. doi:10.1186/1479-5876-12-9.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003;4(7):670–679. Epub 2003 Jun 8.
   Google Scholar
• Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, Scheu S, Pfeffer K, Ware CF, Murphy TL, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol. 2005;6(1):90–98. Epub 2004 Nov 28.
   Google Scholar
• M’Hidi H, Thibult ML, Chetaille B, Rey F, Bouadallah R, Nicollas R, Olive D, Xerri L. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am J Clin Pathol. 2009;132:589–96. doi:10.1309/AJCPPHKGYYGGL39C.
   PubMed Web of Science ®Google Scholar
• Haymaker CL, Wu RC, Ritthipichai K, Bernatchez C, Forget MA, Chen JQ, Liu H, Wang E, Marincola F, Hwu P, et al. BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. OncoImmunology. 2015;4:e1014246–e. doi:10.1080/2162402X.2015.1014246.
   PubMed Web of Science ®Google Scholar
• Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, et al. Exhaustion of tumor-specific CD8+T cells in metastases from melanoma patients.
   Google Scholar